Anlon Healthcare
135.58
-6.84(-4.80%)
Market Cap₹720.63 Cr
PE Ratio37.14
IndustryHealthcare
Company Performance:
1D-4.80%
1M-6.17%
6M+47.80%
1Y+47.80%
5Y+47.80%
View Company Insightsright
More news about Anlon Healthcare
08Dec 25
Anlon Healthcare Shareholders Approve Strategic IPO Fund Reallocation for Acquisitions
Anlon Healthcare Limited successfully secured overwhelming shareholder approval for reallocating ₹2,332.69 lakhs from IPO capital expenditure funds towards strategic acquisitions. The postal ballot voting concluded on January 7, 2026, with 99.99% of votes cast in favor of the resolution, enabling the company to proceed with planned acquisitions of Bizotic Lifescience and Apiqo Organics for inorganic growth.
02Dec 25
Anlon Healthcare Acquires Majority Stake in Apiqo Organics for Rs 5.40 Crore
Anlon Healthcare Limited has entered into a Share Purchase Agreement to acquire a 67.48% stake in Apiqo Organics Private Limited for Rs 5.40 crore. The acquisition involves 55,33,500 equity shares at Rs 9.76 per share. This strategic move aims to enhance Anlon's vertical integration, add 700-800 MT of annual manufacturing capacity for advanced pharmaceutical intermediates, secure critical supply, and strengthen its market position. Apiqo Organics, formerly M/s Apple Life Science, manufactures pharmaceutical intermediates and chemicals. The transaction is expected to close within three months, subject to conditions.
19Nov 25
Anlon Healthcare Showcases Global Reach and Growth in Q2/H1 FY26 Investor Presentation
Anlon Healthcare, a Gujarat-based pharmaceutical intermediates and APIs manufacturer, has released its Q2/H1 FY26 investor presentation. The company reported significant growth, with Q2 FY26 total income increasing by 115.74% to INR 52.23 Cr and PAT rising by 259.85% to INR 9.32 Cr year-on-year. Operating at 84.41% capacity utilization, Anlon has filed 21 DMFs globally. The company's balance sheet shows a net worth of INR 214.32 Cr and reduced long-term borrowings. Strategic initiatives include targeting 10-15 global DMF filings in 5 years, entering the Industrial and Fine chemicals business, and strengthening its leadership team with new appointments.
11Nov 25
Anlon Healthcare Reports Strong Q2 FY26 Results, Plans Capacity Expansion
Anlon Healthcare Limited has reported strong financial results for Q2 FY26. Total income rose 116% to INR 52.32 crore, while profit after tax increased nearly 4 times to INR 9.32 crore. Revenue from operations grew 37.8% to INR 33.29 crore. For the half-year, revenue reached INR 61.99 crore with a profit after tax of INR 12.86 crore. The company's total assets increased to INR 287.52 crore. Anlon Healthcare is planning a 700 metric ton greenfield expansion and exploring inorganic acquisitions, aiming for a 30% revenue CAGR over the next three years.
06Nov 25
Neomile Asset Managers Reduces Stake in Anlon Healthcare Through Open Market Sale
Neomile Asset Managers Private Limited has significantly reduced its stake in Anlon Healthcare Limited through open market transactions between November 3-4, 2025. The firm sold 14,75,992 shares, decreasing its holding from 10.40% to 7.62% of the total share capital, a reduction of 2.78%. Neomile Growth Fund-Series I acted in concert with Neomile Corporate Advisory Limited for this transaction. Anlon Healthcare remains listed on both the National Stock Exchange and Bombay Stock Exchange.
20Sept 25
Anlon Healthcare Unveils Two New Anti-Malarial Products for November 2025 Launch
Anlon Healthcare Limited has successfully developed two new anti-malarial products, Artemether and Lumefantrine. The company plans to launch these medications in November 2025, marking a significant expansion of its product portfolio. This development aligns with Anlon Healthcare's strategy to diversify its offerings and address global health concerns. The announcement was made in compliance with SEBI regulations, with further updates expected as the launch date approaches.
15Sept 25
Anlon Healthcare Limited Reports Shareholding Change Following Equity Share Acquisition
Anlon Healthcare Limited has disclosed a substantial change in its shareholding structure following an acquisition of equity shares. The company has notified both BSE and NSE about this change, complying with SEBI regulations. The disclosure was made on September 13, as per LODR data, and was signed by Managing Director Punitkumar Rasadia. While specific details of the shareholding change were not provided, such disclosures typically indicate a substantial acquisition or change in company ownership.
Anlon Healthcare
135.58
-6.84
(-4.80%)
1 Year Returns:+47.80%
Industry Peers
Sun Pharmaceutical
1,736.00
(+0.35%)
Divis Laboratories
6,485.50
(-1.98%)
Torrent Pharmaceuticals
3,949.80
(-0.34%)
Cipla
1,465.20
(-0.03%)
Dr Reddys Laboratories
1,215.50
(+0.45%)
Lupin
2,188.40
(+0.28%)
Mankind Pharma
2,224.30
(+1.07%)
Zydus Life Science
895.05
(+0.02%)
Alkem Laboratories
5,867.00
(+1.17%)
Aurobindo Pharma
1,172.90
(-2.15%)